Technical analysis of Cue Biopharma, Inc. (CUE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic.
Price Performance
| 1 month | +32.96% |
| 3 months | +20.06% |
| Year-to-date | +273.03% |
| 1 year | +57.68% |
| 3 years | -52.54% |
| 5 years | -91.18% |
52-Week Range
| 52-week High | $45.50 |
| 52-week Low | $4.97 |
| Avg Volume (90d) | 149K |
Technical Indicators
| SMA 50 | $29.34 |
| SMA 200 | $19.27 |
| Beta | 1.58 |
| 30-day Volatility (annualised) | 114.3% |
| Price vs SMA 50 | +16.5% |
| Price vs SMA 200 | +77.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $23.03 | |
| 2025-11 | $18.90 | -17.9% |
| 2025-12 | $9.16 | -51.5% |
| 2026-01 | $10.04 | +9.6% |
| 2026-02 | $8.40 | -16.3% |
| 2026-03 | $6.90 | -17.9% |
| 2026-04 | $14.74 | +113.6% |
| 2026-05 | $21.90 | +48.6% |
| 2026-06 | $31.56 | +44.1% |
| 2026-07 | $26.84 | -15.0% |
| 2026-08 | $25.52 | -4.9% |
| 2026-09 | $34.17 | +33.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $34.17 |
| Market Cap | $90M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.34 |
| EV / EBITDA | -0.27 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.16 |
| Current Ratio | 2.74 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -11.88 |